EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Safety of Immune Checkpoint Inhibitors in Hepatitis B Virus-Positive Cancer Patients: A Multicenter Retrospective Cohort Study

Meshail Baswaid, Alaa Shahbar iD, Afnan Noor, Danyah Ahmed Katlan, Abdulfattah Alhazmi iD, Mohammed Alnuhait iD, Aryaf Alsulami, Baker Saemaldaher, Hussam Magliah

Current Oncology · 06.08.2026 · 33 (8) · 469

DOI: 10.3390/curroncol33080469 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 06.08.2026. Verfasst von Meshail Baswaid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Care Department, International Medical Center Hospital, Jeddah 23214, Saudi Arabia. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis B virus, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, but their safety in patients with pre-existing hepatitis B virus (HBV) infection remains uncertain. HBV reactivation is a recognized complication of immunosuppressive cancer therapy, yet evidence supporting routine antiviral prophylaxis during ICI treatment is limited. This study evaluated HBV reactivation and HBV-related outcomes among HBV-positive cancer patients receiving ICIs.

Methods

This multicenter retrospective cohort study included adult patients treated with ICIs between January 2017 and December 2022. Patients were grouped according to receipt of antiviral prophylaxis. The primary outcome was HBV reactivation during ICI therapy. Secondary outcomes included hepatic flare, severity, and timing of reactivation, response to antiviral therapy, and factors associated with HBV-related outcomes.

Results

A total of 160 patients were included; 68 received antiviral prophylaxis and 92 did not. HBV reactivation occurred in 3 patients (1.9%) and the odd ratio between antiviral prophylaxis and HBV reactivation was wide and imprecise (2.76; 95% CI 0.25–31.05). Hepatic flare occurred in 16 patients (10.0%) and was more frequent in the prophylaxis group than in the no-prophylaxis group (19.1% vs. 3.3%; p = 0.001).

Conclusion

In this multicenter retrospective cohort study, the HBV reactivation rate was low and could not determine whether antiviral prophylaxis reduced the risk of reactivation. Hepatic flares were significantly more common among patients who received antiviral prophylaxis, likely reflecting a higher baseline risk of HBV-related complications in this group. A future randomized controlled trial is warranted to guide risk-adapted antiviral prophylaxis and monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis BHepatitis B virusImmune Checkpoint InhibitorsNeoplasmsAgedFemaleHumansMaleMiddle AgedAntiviral AgentsRetrospective StudiesVirus Activation

Stichwörter der Autor:innen

HBV reactivationantiviral prophylaxiscancer immunotherapyhepatitis B virusimmune checkpoint inhibitors

Substanzen

Antiviral AgentsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Pharmaceutical Care Department, International Medical Center Hospital, Jeddah 23214, Saudi Arabia.
  • Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
  • Pharmaceutical Care Department, King Faisal Specialist Hospital & Research Center, Jeddah 22234, Saudi Arabia.
  • Pharmaceutical Care Department, King Fahad Armed Forces Hospital, Jeddah 23311, Saudi Arabia.
  • Department of Clinical Pharmacy, College of Pharmacy, Shaqra University, Al-Dawadmi 11961, Saudi Arabia.
  • College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah 21423, Saudi Arabia.

ORCID-Profile: Alaa Shahbar, Abdulfattah Alhazmi, Mohammed Alnuhait

Zitieren

APA

Baswaid, M., Shahbar, A., Noor, A., Katlan, D. A., Alhazmi, A., Alnuhait, M., Alsulami, A., Saemaldaher, B., & Magliah, H. (2026). Safety of Immune Checkpoint Inhibitors in Hepatitis B Virus-Positive Cancer Patients: A Multicenter Retrospective Cohort Study. Current Oncology, 33(8), 469. https://doi.org/10.3390/curroncol33080469

Vancouver

Baswaid M, Shahbar A, Noor A, Katlan DA, Alhazmi A, Alnuhait M, et al. Safety of Immune Checkpoint Inhibitors in Hepatitis B Virus-Positive Cancer Patients: A Multicenter Retrospective Cohort Study. Current Oncology. 2026;33(8):469. doi:10.3390/curroncol33080469

BibTeX
@article{Baswaid2026,
  author = {Baswaid, Meshail and Shahbar, Alaa and Noor, Afnan and Katlan, Danyah Ahmed and Alhazmi, Abdulfattah and Alnuhait, Mohammed and Alsulami, Aryaf and Saemaldaher, Baker and Magliah, Hussam},
  title = {Safety of Immune Checkpoint Inhibitors in Hepatitis B Virus-Positive Cancer Patients: A Multicenter Retrospective Cohort Study},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {8},
  pages = {469},
  doi = {10.3390/curroncol33080469}
}
Kostenlos starten →